Asenapine

BreastfeedingGeriatricPediatric
  • TRADE NAME: Saphris (Merck)
  • INDICATIONS: Schizophrenia, bipolar disorder
  • CLASS: Antipsychotic
  • HALF-LIFE: 24 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Alcohol, Amiodarone, Chlorpromazine, CYP2D6 substrates and inhibitors, Fluvoxamine, Gatifloxacin, Moxifloxacin, Paroxetine Hydrochloride, Procainamide, QT prolonging drugs, Quinidine, Sotalol, Thioridazine, Ziprasidone

PREGNANCY CATEGORY: C

INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

See full prescribing information for complete boxed warning.

Our database has 62 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
HEMATOLOGIC
NEUROMUSCULAR/SKELETAL
OTHER


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of asenapine in the Informa Healthcare journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top